【摘要】：正近年來惡性腫瘤的發(fā)病率逐年上升,在中國(guó)已成為人類健康的最大威脅。紫杉醇的抗腫瘤活性發(fā)現(xiàn)于20世紀(jì)70年代,臨床應(yīng)用已超過20年~([1])。廣泛應(yīng)用于食管癌、胃癌、肺癌、卵巢癌、乳腺癌及宮頸癌等多種腫瘤~([2])。其主要作用機(jī)制是抑制微管解聚,從而阻斷腫瘤細(xì)胞復(fù)制,最終發(fā)揮其抗腫瘤的作用~([3])。據(jù)統(tǒng)計(jì),有高達(dá)16%的惡性腫瘤患者同時(shí)患有糖尿病。目前國(guó)內(nèi)外對(duì)于合并糖尿病這一危險(xiǎn)因
[Abstract]:In recent years, the incidence of malignant tumors has increased year by year, and has become the greatest threat to human health in China. The antitumor activity of paclitaxel was found in 1970's, and it has been used in clinic for more than 20 years. It is widely used in many kinds of tumors, such as esophageal cancer, gastric cancer, lung cancer, ovarian cancer, breast cancer and cervical cancer. Its main mechanism is to inhibit microtubule depolymerization, thereby blocking the replication of tumor cells, and finally exert its anti-tumor action ~ ([3]). According to statistics, up to 16% of patients with malignant tumors also suffer from diabetes. At present, the risk of diabetes mellitus at home and abroad
【作者單位】： 新疆醫(yī)科大學(xué)附屬腫瘤醫(yī)院心肺功能科;
【分類號(hào)】：R730.5;R587.1
，

本文編號(hào)：2471633